dextrothyroxine (choloxin) Report issue

Small molecule Approved FDA Priority Review FDA
AACT ChEMBL DrugBank Drug Central Drugs@FDA KEGG MeSH PubChem repoDB

Active Ingredient History

NOW
  • Now
Dextrothyroxine is a dextrorotary isomer of thyroxine. It saw research as a cholesterol-lowering drug but was pulled due to cardiac side-effects. It increases hepatic lipase which in turn improves utilization of triglycerides and decreases levels of lipoprotein(a) in blood serum.   Wikipedia

Chemistry

More Chemistry

Pharmacology

  • Mechanism of Action:
  • Multi-specific: Missing data
  • Black Box: No
  • Availability: Prescription Only
  • Delivery Methods: Oral
  • Pro Drug: No

Alternative names

dextrothyroxine | dextrothyroxine sodium | d-t4 | d-thyroxine | sodium dextrothyroxine | t4 (liotrix) | thyroxine

Organizations (14)

Research & Development (13)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (1)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (10)

Approved Indications (1)


 

Hypercholesterolemia (approved 1967)

Experimental Indications - Clinical Trial Phases 1-4 (9)


 

Cardiovascular Diseases (Phase 3)

Coronary Disease (Phase 3)

Heart Diseases (Phase 3)

Hyperlipidemias (Phase 4)

Hypopituitarism (Phase 4)

Hypothyroidism (Phase 4)

Myocardial Infarction (Phase 3)

Myocardial Ischemia (Phase 3)

Pediatrics (Phase 3)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 10
  • # of Trial Organizations: 13

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue